NASDAQ:HSIC - Henry Schein Stock Price, Price Target & More

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Henry Schein's stock split on the morning of Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly created shares were issued to shareholders after the market closes on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

Henry Schein announced that its board has approved a stock buyback program on Tuesday, September 19th 2017, which allows the company to repurchase $400,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to reacquire up to 6.3% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company's board of directors believes its shares are undervalued.

Henry Schein, Inc. (NASDAQ:HSIC) posted its quarterly earnings data on Tuesday, May, 8th. The company reported $0.95 EPS for the quarter, topping analysts' consensus estimates of $0.92 by $0.03. The business earned $3.22 billion during the quarter, compared to analyst estimates of $3.18 billion. Henry Schein had a net margin of 3.18% and a return on equity of 19.68%. The firm's quarterly revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.88 EPS. View Henry Schein's Earnings History.

Henry Schein updated its FY18 earnings guidance on Tuesday, May, 8th. The company provided earnings per share guidance of $4.03-4.14 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.09.

19 analysts have issued 1-year price objectives for Henry Schein's stock. Their forecasts range from $73.00 to $102.00. On average, they expect Henry Schein's stock price to reach $81.50 in the next year. View Analyst Ratings for Henry Schein.

Henry Schein saw a increase in short interest during the month of May. As of May 31st, there was short interest totalling 20,773,220 shares, an increase of 12.3% from the May 15th total of 18,492,187 shares. Based on an average trading volume of 1,381,966 shares, the days-to-cover ratio is presently 15.0 days. Currently, 13.7% of the company's shares are sold short. View Henry Schein's Current Options Chain.

Some companies that are related to Henry Schein include Boston Scientific (BSX), Zoetis (ZTS), Illumina (ILMN), Humana (HUM), BEXIMCO PHARMAC/S GDR REGS (BXP), Vertex Pharmaceuticals (VRTX), Baxter International (BAX), HCA Healthcare (HCA), Regeneron Pharmaceuticals (REGN), Edwards Lifesciences (EW), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Fresenius Medical Care AG & Co. (FMS), ESSILOR Intl S/S (ESLOY) and Actelion (ALIOF).

Media stories about HSIC stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Henry Schein earned a news impact score of 0.18 on Accern's scale. They also assigned news stories about the company an impact score of 45.62 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Henry Schein's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.50%), Select Equity Group L.P. (4.20%), Alecta Pensionsforsakring Omsesidigt (3.57%), JPMorgan Chase & Co. (1.66%), Atlanta Capital Management Co. L L C (1.61%) and Swedbank (1.41%). Company insiders that own Henry Schein stock include Barry J Alperin, Donald J Kabat, Gerald A Benjamin, James A Harding, Kurt P Kuehn, Lorelei Mcglynn, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Paul Brons, Paul Rose, Philip A Laskawy and Steven Paladino. View Institutional Ownership Trends for Henry Schein.

HSIC stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Green Valley Investors LLC, BlackRock Inc., Virginia Retirement Systems ET AL, Glen Harbor Capital Management LLC, Neuberger Berman Group LLC, Russell Investments Group Ltd. and Swedbank. Company insiders that have sold Henry Schein company stock in the last year include Barry J Alperin, Mark E Mlotek, Paul Brons and Paul Rose. View Insider Buying and Selling for Henry Schein.

HSIC stock was bought by a variety of institutional investors in the last quarter, including Select Equity Group L.P., American Century Companies Inc., Kovitz Investment Group Partners LLC, Wells Fargo & Company MN, Alecta Pensionsforsakring Omsesidigt, New York State Common Retirement Fund, Polar Asset Management Partners Inc. and The Manufacturers Life Insurance Company. View Insider Buying and Selling for Henry Schein.

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HSIC stock can currently be purchased for approximately $74.69.

Henry Schein has a market capitalization of $11.10 billion and generates $12.46 billion in revenue each year. The company earns $406.29 million in net income (profit) each year or $3.60 on an earnings per share basis. Henry Schein employs 22,000 workers across the globe.

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at 631-843-5500 or via email at [email protected]